GSK Bio
NEWS
The American West could see some significant growth in the number of biotech jobs as companies are eying at least two states for expansions.
The company is seeking the funds to continue to drive the development of its lead candidates, nirogacestat, a gamma-secretase inhibitor for the treatment of desmoid tumors and PD-0325901, a MEK inhibitor for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas.
Biopharma companies strengthen their executive ranks and boards with new additions.
Kadans expands its presence in the United Kingdom by adding its second research hub in the country to its Pan-European science park portfolio.
Jack Bailey, head of the company’s U.S. pharmaceuticals business is stepping down at the end of the year.
A new UK-based biotech company, AstronauTx Ltd, which builds on the work from the Alzheimer’s Research UK UCL Drug Discovery Institute (DDI), has received an investment of £6.5 million from the Dementia Discovery Fund (DDF).
Biopharma companies strengthen their senior leadership teams and boards of directors.
The vaccines are for Ebola Zaire, Ebola Sudan and the Marburg virus. Currently no licensed vaccines against these three viruses are available. All three diseases have a death rate of about 50%.
The new company will be helmed by Mylan’s Michael Goettler and is expected to generate 2020 revenues of $19 to $20 billion.
JOBS
IN THE PRESS